scholarly article | Q13442814 |
P50 | author | Stuart M Pitson | Q40447668 |
P2093 | author name string | Olivier Cuvillier | |
Pascal Rischmann | |||
Bernard Malavaud | |||
Catherine Mazerolles | |||
Dimitri Pchejetski | |||
Nicolas Doumerc | |||
Cyril Calvet | |||
Geisilène Russano de Paiva | |||
P2860 | cites work | Cancer statistics, 2009 | Q29547625 |
P433 | issue | 18 | |
P921 | main subject | prostate cancer | Q181257 |
P304 | page(s) | 3417-3424 | |
P577 | publication date | 2010-10-20 | |
P1433 | published in | European Journal of Cancer | Q332260 |
P1476 | title | Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens | |
P478 | volume | 46 |
Q41661043 | "Dicing and Splicing" Sphingosine Kinase and Relevance to Cancer. |
Q52663621 | ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. |
Q92451777 | Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase |
Q44592773 | C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth |
Q37619251 | Ceramide signaling in mammalian epidermis |
Q39399921 | Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection |
Q33799125 | Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1. |
Q41061525 | Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer |
Q39207332 | Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1. |
Q27009557 | Export of sphingosine-1-phosphate and cancer progression |
Q90456543 | Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors |
Q60951976 | Grape Seed Proanthocyanidin Extract Inhibits Human Esophageal Squamous Cancerous Cell Line ECA109 via the NF-B Signaling Pathway |
Q33275396 | High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis |
Q53256892 | Immunohistochemical Detection of Sphingosine-1-Phosphate and Sphingosine Kinase-1 in Human Tissue Samples and Cell Lines. |
Q64973473 | Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. |
Q34373466 | Interdiction of sphingolipid metabolism to improve standard cancer therapies |
Q26786149 | Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma |
Q33829692 | Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget |
Q39001159 | Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. |
Q38795539 | Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway |
Q40978323 | Overexpression of sphingosine kinase 1 is predictive of poor prognosis in human breast cancer |
Q36511320 | Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity |
Q47193833 | Predictive and prognostic value of sphingosine kinase 1 expression in patients with invasive ductal carcinoma of the breast |
Q33649823 | Re-configuration of sphingolipid metabolism by oncogenic transformation |
Q89587308 | S1P Signaling in the Tumor Microenvironment |
Q35108994 | Sphingosine kinase 1 and cancer: a systematic review and meta-analysis |
Q35794452 | Sphingosine kinase 1 as an anticancer therapeutic target |
Q33853998 | Sphingosine kinase 1 in cancer |
Q27853204 | Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer |
Q33636769 | Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer |
Q34428778 | Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation |
Q33631908 | Sphingosine kinase 1 isoform-specific interactions in breast cancer |
Q92683744 | Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine |
Q28069459 | Sphingosine-1 Phosphate: A New Modulator of Immune Plasticity in the Tumor Microenvironment |
Q50665340 | Sphingosine-1-phosphate/sphingosine kinase 1-dependent lymph node metastasis in esophageal squamous cell carcinoma |
Q37905015 | Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy |
Q35831148 | TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis |
Q49714600 | TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition |
Q30301001 | The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines |
Q90070054 | The dysfunctional lipids in prostate cancer |
Q26748927 | The emerging role of FTY720 (Fingolimod) in cancer treatment |
Q37930972 | Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer |
Q35264010 | Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde |
Search more.